W.L.Gore & Associates
Trial Pipeline
GORE® Ascending Stent Graft in the Treatment of De Novo Type A Aortic Dissections
NCT06827990
Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance
NCT06658730
Real-World Data Collection of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis When Used in Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) to Treat Aortoiliac Occlusive Disease
NCT06872905
Tissue Reinforcement for Breast Reconstruction (TRBR) Pivotal Clinical Study (REDEFINE)
NCT06556654
Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
NCT06218875
The GORE VBX FORWARD Clinical Study: A Comparison of the GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis to Bare Metal Stenting for Patients With Complex Iliac Occlusive Disease
NCT05811364
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
NCT05489588
GORE® ENFORM Biomaterial Product Study
NCT04718168
A Study to Evaluate the Safety and Effectiveness of the InnAVasc Arteriovenous Graft for Hemodialysis Access in Patients With End-Stage Renal Disease
NCT04671771
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
NCT03821129
Assessment of GORE® SYNECOR Biomaterial in Focused Patient Populations and Long-Term Application
NCT05094089
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05409976
Evaluation of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis in the Treatment of Thoracoabdominal and Pararenal Aortic Aneurysms
NCT03728985
Evaluation of the GORE PV1 Device in Patients With Pulmonary Valve Dysfunction
NCT03441971
Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis in the Treatment of Abdominal Aortic Aneurysms
NCT02489539
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 2
NCT02777593
Evaluation of the GORE® TBE Device in the Treatment of Lesions of the Aortic Arch and Descending Thoracic Aorta, Zone 0/1
NCT02777528
ARISE: Evaluation of the GORE® Ascending Stent Graft in the Treatment of DeBakey Type I/II Aortic Dissection
NCT02380716
Global Registry for Endovascular Aortic Treatment (GREAT)
NCT01658787
Early Feasibility of the Branched TAG® Device in the Treatment of Aortic Arch Aneurysms
NCT02264977
Evaluation of the GORE® EXCLUDER® Iliac Branch Endoprosthesis
NCT01883999
The Gore SCAFFOLD Clinical Study
NCT01901874
Evaluation of the GORE TIGRIS Vascular Stent
NCT01576055
GORE® Septal Occluder Device for Patent Foramen Ovale (PFO) Closure in Stroke Patients
NCT00738894
GORE VIABAHN Endoprosthesis With Heparin Bioactive Surface in the Treatment of SFA Obstructive Disease (VIPER)
NCT00541307
GORE TAG® Thoracic Endoprosthesis - 45 mm for the Treatment of Aneurysms of the Descending Thoracic Aorta
NCT00608829
GORE Embolic Protection With Reverse Flow
NCT00594100
GORE-TEX PROPATEN Vascular Graft Study
NCT00205790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for W.L.Gore & Associates Shows
According to the ClinicalTrials.gov registry, W.L.Gore & Associates is linked to 117 US clinical trials across every stage of research activity. Of those, 99 studies are currently recruiting — about 85% of the sponsor's indexed portfolio — and 9 are already marked complete, representing roughly 8% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for W.L.Gore & Associates reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for W.L.Gore & Associates is Aortic Aneurysm, Thoracic with 3 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.